Nom du produit:1-{[1-(3-ethylphenyl)-1H-1,2,3-triazol-4-yl]carbonyl}piperidin-4-amine
IUPAC Name:1-[1-(3-ethylphenyl)-1H-1,2,3-triazole-4-carbonyl]piperidin-4-amine
| Unité d'emballage | Stock disponible | Prix($) | Quantité |
|---|---|---|---|
| CM495031-1g | 1-2 Weeks | ƿǶǑ |
|
|
|||
| Product Overview |
1-{[1-(3-ethylphenyl)-1H-1,2,3-triazol-4-yl]carbonyl}piperidin-4-amine, also known as EPTP, is a chemical compound that has gained significant attention in the field of scientific research. This compound belongs to the class of piperidines and is a triazole-based inhibitor of the protein kinase B (PKB/Akt) signaling pathway. |
| Synthesis and Application |
The synthesis of 1-{[1-(3-ethylphenyl)-1H-1,2,3-triazol-4-yl]carbonyl}piperidin-4-amine involves the reaction of 4-aminopiperidine with 3-ethylphenylisocyanate and 1H-1,2,3-triazole-4-carboxylic acid in the presence of a coupling agent such as N,N'-diisopropylcarbodiimide (DIC) or N,N'-dicyclohexylcarbodiimide (DCC). The reaction is carried out in a suitable solvent such as dimethylformamide (DMF) or dimethyl sulfoxide (DMSO) at room temperature, and the product is obtained after purification by column chromatography. 1-{[1-(3-ethylphenyl)-1H-1,2,3-triazol-4-yl]carbonyl}piperidin-4-amine has been extensively studied for its potential therapeutic applications in various diseases, including cancer, diabetes, and neurodegenerative disorders. It has been found to inhibit the activity of PKB/Akt, a key signaling pathway that plays a critical role in cell survival, proliferation, and metabolism. Inhibition of this pathway has been shown to induce apoptosis (programmed cell death) and suppress tumor growth in various cancer cell lines. 1-{[1-(3-ethylphenyl)-1H-1,2,3-triazol-4-yl]carbonyl}piperidin-4-amine has also been found to improve glucose metabolism and insulin sensitivity in diabetic animal models. Furthermore, it has been shown to protect against neuronal damage and cognitive impairment in neurodegenerative disease models. |
| Future Directions |
Future directions for 1-{[1-(3-ethylphenyl)-1H-1,2,3-triazol-4-yl]carbonyl}piperidin-4-amine research include the development of more potent and selective analogs, optimization of its pharmacokinetic properties, and evaluation of its efficacy and safety in human clinical trials. Furthermore, the potential use of 1-{[1-(3-ethylphenyl)-1H-1,2,3-triazol-4-yl]carbonyl}piperidin-4-amine as a combination therapy with other anticancer agents or as a radiosensitizer in cancer treatment is an area of active investigation. Additionally, the role of 1-{[1-(3-ethylphenyl)-1H-1,2,3-triazol-4-yl]carbonyl}piperidin-4-amine in other diseases, such as cardiovascular and inflammatory disorders, warrants further investigation. |
Recherche 
+86 21 5895 0110 
